Recommended Global Immunology Conferences
Tumor & Cancer Immunology 2018
With the enormous response from the previous annual Tumor & Cancer Immunology conference 2017, ConferenceSeries Ltd invites all the participants from all over the world to attend 3rd International Conference on Tumor & Cancer Immunology-2018” during September 17-18, 2018 in San Diego, USA which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions. The Tumor & Cancer Immunology Conference hosting presentations from editors of prominent refereed journals, renowned and active investigators and decision makers in the field of Immunology.
Tumor & Cancer Immunology -2018 Conference deals with the diagnosis, prevention, and treatment of diseases of the organ specific cancers and including the latest techniques. Tumor & Cancer Immunology 2018 is an extraordinary event designed for International medical health professionals and oncologists to facilitate the dissemination and application of research findings related to Cancer. Head and Neck Cancer The conference invites participants from all leading universities, clinical research institutions and diagnostic companies to share their research experiences on all aspects of this rapidly expanding field and thereby, providing a showcase of the latest techniques. Tumor & Cancer Immunology 2018 provides two days of robust discussions on methods and strategies related to management and quality improvement of Cancer therapy, Tumor Biomarkers as well as explore new ideas and concepts on a global scale and the topics include breast cancer, leukaemia, bone cancer, lung cancer, prostate cancer, thyroid cancer, blood cancer, colon cancer and cervical cancer.
Why to attend??
With members from around the world focused on learning about Tumor or Cancer immunology and its advances: this is your best opportunity to reach the largest assemblage of participants from Tumor & Cancer immunology community. conduct presentations, distribute information’s, meet with current and potential scientists, make a splash with new drug developments, and receive name recognition at this 2-day event, world-renowned speakers, the most recent techniques, developments, and the newest updates in Tumor & Cancer immunology are hallmarks of this conference.
- Tumor & Cancer research Students, Scientists
- Tumor & Cancer Researchers
- Tumor & Cancer research Faculty
- Medical Colleges
- Tumor or Cancer research Associations and Societies
- Business Entrepreneurs
- Training Institutes
- Manufacturing Medical Devices Companies
Join us in San Diego, USA for the leading annual Tumor & Cancer immunology 2018 event and
Find the latest developments in immunology and immunotherapy
Lectures by the world's prominent Tumor Researchers, oncologist and poster presentations at every career stage.
Network Tumor immunology and Immunotherapy with colleagues from more than 50 countries
Awareness on novel tools and techniques to benefit your research.
Sessions & Tracks
Track 1: Tumors
- To help diagnose conditions, as in the case of identifying early stage cancers (Diagnostic)
- To forecast how aggressive a condition is, as in the case of determining a patient's ability to fare in the absence of treatment (Prognostic)
- To predict how well a patient will respond to treatment (Predictive)
Track 20: Cancer Genomics and Metabolomics
Cancer genomics is the study of the totality of DNA sequence and gene expression differences between tumor cells and normal host cells. It aims to understand the genetic basis of tumor cell proliferation and the evolution of the cancer genome under mutation and selection by the body environment, the immune system and therapeutic interventions. Metabolomics research is being used to discover diagnostic cancer biomarkers in the clinic, to better understand its complex heterogeneous nature, to discover pathways involved in cancer that could be used for new targets and to monitor metabolic biomarkers during therapeutic intervention. These metabolomics approaches may also provide clues to personalized cancer treatments by providing useful information to the clinician about the cancer patient’s response to medical interventions. The ultimate goal of most metabolomics cancer studies is to discover cancer-specific diagnostic, prognostic or predictive biomarkers for a patient.
Track 21: Cancer & HIV
People infected with HIV have a substantially higher risk of some types of cancer compared with uninfected people of the same age. Three of these cancers are known as "acquired immunodeficiency syndrome (AIDS)-defining cancers" or "AIDS-defining malignancies": Kaposi sarcoma, non-Hodgkin lymphoma, and cervical cancer. A diagnosis of any one of these cancers marks the point at which HIV infection has progressed to AIDS. A compromised immune system can increase a person’s risk for cancer. It can also allow for cancer cells to spread faster than in someone without HIV. With the use of antiretroviral therapy (ART), the rates of AIDS-related cancers have dropped significantly. At the same time, people with HIV are at higher than average risk for several other cancers, including Hodgkin lymphoma and cancers of the anus, lung, liver, and skin, The number of cases of these other cancers is increasing in people with HIV.
Track 23: Novel Approaches in Cancer & Tumor
Immunotherapy encompasses several different treatment approaches, each of which has a distinct mechanism of action, and all of which are designed to boost or restore immune function in some manner. This includes: Monoclonal antibodies, Immune checkpoint inhibitors, Therapeutic Cancer vaccines, cytokines, and other non-specific immunotherapies.
Past Conference Report
Tumor & Cancer immunology 2017
Tumor & Cancer Immunology-2017: Past Conference Report
Conference series LLC hosted the “2nd International Conference on Tumor & Cancer Immunology and Immunotherapy” during July 17-18, 2017 at Doubletree by Hilton Chicago North Shore Conference Center, 9599 Skokie Boulevard, Skokie, Illinois, 60077-1314, Chicago, USA with the theme “Emerging Technologies and treatment in Tumor & Cancer immunotherapy from vaccines to antibodies and cell therapies” was a great success, where eminent keynote speakers from various reputed institutions and organizations with their resplendent presence addressed the gathering.
Benevolent response and active participation was received from the renowned experts and Editorial Board Members of Conference series Journals as well as from the Immunologists, Scientists, Researchers, Students and Leaders in Cancer research, Tumor related research field, Immunology, who made this event successful.
The Conference was carried out through various informative and cutting edge sessions, in which the discussions were held on the following thought provoking and cerebrating scientific tracks:
- Antibody Therapy of Cancer
- Tumor Immunogenicity
- Brain Tumors
- Immunotherapy - Tumors
- Tumor Immunology
- Cancer vaccines
- Cancer Immunology & Immunotherapy
- Immune checkpoint inhibitors
- Cancer Research
- Combining Cancer Immunotherapies
- Tumor immunotherapy research
- Cancer micro and immuno environment
- Tumor markers and drug targeting
- Cancer clinical trials
- Tumor biology
- Cancer biomarkers
- Immuno-Oncology studies
- Immunotherapy Monitoring
- Engineered T-Cell Therapy
- Novel Approaches in Cancer & Tumor
The conference was embarked with an opening ceremony followed by a series of lectures delivered by Honorable Guests and members of the Keynote forum. The adepts who promulgated the theme with their exquisite talk were:
· Roza Nurieva, MD Anderson Cancer Center, USA
· Jennifer Wu, Medical University of South Carolina, USA
· Gopal Krishnan, Promega Corporation, USA
· Marc Delcommenne, Rush University Medical Center, USA
All the above mentioned Honorable Guests and Keynote speakers gave their energetic and fruitful contributions and special thanks to our Honorable Moderator Manal Mohamed Saber, for her remarkable contribution towards smooth functioning at Tumor & Cancer Immunology-2017 Conference.
Conference Sessions Chairs:
· Qiao Li, University of Michigan, USA
· Roza Nurieva, MD Anderson Cancer Center, USA
We congratulate Naoki Ohtsu, from Hokkaido University, Japan for winning Best Poster Award for the topic “Inhibition of Eva1 degrade the formation and development of glioblastomas”.
Conference Series LLC offers its heartfelt appreciation to Societies and Organizations includes Guardant Health, Crowd Reviews, Bio-equip, Bio Events, Pharma Voice and is also obliged to the Organizing Committee Members, adepts of field, various outside experts, company representatives and other eminent personalities who interlaced with Conference series LLC in supporting and making the conference as never before one.
Your rejoinder is our inspiration; keeping this motto in mind and being witnessed the triumph of Tumor & Cancer Immunology-2017, Conference Series LLC is delighted to announce the next event. Mark your calendars for the upcoming extravaganza, “3rd International Conference on Tumor & Cancer Immunology & Immunotherapy” to be held during September 17-18, 2018 at San Diego, USA.
Let us meet again @ Tumor & Cancer Immunology-2018
Past Reports Proceedings Gallery